#### Concordia University - Portland CU Commons

Math & Science Department (SURI)

Summer Undergraduate Research Institute (SURI)

1-1-2011

## Development of a Novel GC/MS Method for the Detection of Nicotinamide and Activity of ADP-Ribosylating Toxins

Lindsay R. Lermo *Concordia University - Portland* 

Thomas O. Munson Concordia University - Portland

Michael H. Godsey Concordia University - Portland, mgodsey@cu-portland.edu

Follow this and additional works at: http://commons.cu-portland.edu/suri\_msd Part of the <u>Chemistry Commons</u>

#### **Recommended** Citation

Lermo, Lindsay R.; Munson, Thomas O.; and Godsey, Michael H., "Development of a Novel GC/MS Method for the Detection of Nicotinamide and Activity of ADP-Ribosylating Toxins" (2011). *Math & Science Department (SURI)*. 1. http://commons.cu-portland.edu/suri\_msd/1

This Poster is brought to you for free and open access by the Summer Undergraduate Research Institute (SURI) at CU Commons. It has been accepted for inclusion in Math & Science Department (SURI) by an authorized administrator of CU Commons. For more information, please contact libraryadmin@cu-portland.edu.



#### **Abstract / Introduction**




Figure 1 – Nicotinamide adenine diphosphate is broken by ADP-ribosylating toxins to release nicotinamide.

ADP-ribosylating break toxin enzymes NADH (Figure 1) and transfer the ADPribosyl group to a residue on a target protein, permanently inactivating or denaturing the protein. This activity is typically detected with a radioassay, which is expensive and requires radioactive materials.

ADP-ribosylation corresponds with the release of nicotinamide. It is possible to detect nicotinamide with a Gas Chromatograph/Mass Spectrometer (GC/MS) (Jacobson, Dame, Pyrek & Jacobson, 1995). The purpose of this study is to measure ADP-ribosylation activity using GC/MS by detecting the liberated By nicotinamide. derivatizing the nicotinamide, the detection limit was lowered to 0.5 ng/ $\mu$ l. Control measurements of ADPribosylation activity by a cholera toxin protein nicotinamde levels of found low contamination.

## Materials

All GC/MS scans were performed on a HP GC/MS (Model 5890 gas chromatograph and 5972 mass selective detector with a 7673 GC/SFC auto-injector and a DB-5 column by J&W Scientific. Agilent Technologies, Inc.)

Abbreviations used: BSTFA + TMCS: (N,O-Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane Ctx: Cholera toxin

# **Development of a novel GC/MS method for the detection of** nicotinamide and activity of ADP-ribosylating toxins

Lindsay R. Lermo, Thomas O. Munson, Michael H. Godsey Concordia University, Portland, OR

#### **Nicotinamide Detection**

Extensive testing was done to analyze the lowest concentration of nicotinamide that could be detected on a GC/MS.

$H_{1}C$ $CH_{3}$ $CF_{3}$ $CH_{3}$	ł
	F
Si_NSi_Si-CH <sub>3</sub>	r
H <sub>3</sub> C <sup>N</sup> CH <sub>3</sub>	

Figure 2 – **BSTFA silanizing** reagent

It was determined that optimum detection was found when the nicotinamide was derivatized with a silvl group (Figure 2) and dissolved in methylene chloride.

: C:\HPCHEM\1\DATA\0726103.D Operator Acquired : 26 Jul 2010 7:11 pm using AcqMethod SVDEF Instrument : GC/MS #3 Sample Name: .5ng/ul nam anion Misc Info : Vial Number: TIC: 0726103.0 Scan 1290 (12.227 min): 0726103.D

**Figure 3 – Nicotinamide detection with standard** volatiles method at a .5 ng/ $\mu$ l concentration.

### **Results/Discussion**

Nicotinamide is detectable on the GC/MS with the proper solvent and derivatizing steps.

Nicotinamide detection can be improved by the use of selected ion monitoring methods

These results show that there is nicotinamide contamination in the control reaction. It appears the NAD may be hydrolyzing in the absence of enzyme or contaminated with nicotinamide.

#### **ADP-ribosylation detection**


After developing a GC/MS system for the detection of low levels of nicotinamide, we began to pursue a method for the detection of ADP-ribosylation. Toxin protein and substrate concentrations used in the initial assay were upon literature review (Moss, based Maganiello & Vaughn, 1976) Cholera toxin (Ctx) was chosen as a model ADPribosyltransferase protein.

-Mix the toxin with the substrate in the correct quantities in a screw-top GC/MS target vial. -Incubate RT 2 hr to allow reaction to proceed

-Dessicate in a drying oven at 100°C to remove water.

-Dissolve remnants in 150µL pyridine and derivatize with BSTFA. - Bring to 1 mL with methylene chloride. -Analyze on GC/MS.

Results are compared in Figure 4.



**Figure 4 – A comparison of the GC/MS information.** The image on the left is nicotinamide detected in a vial that did not contain Ctx. On the right is nicotinamide detected in a vial containing Ctx and NADH.

The method will be improved by determining and mitigating the source of nicotinamide contamination. Research is being conducted using higher purity NAD, as well as adjusting aspects of the procedure to reduce possible non-enzymatic hydrolysis of the NADH. Hopefully, these methods will reduce the level of nicotinamide present in the control reactions and allow for the measurement of low levels of nicotinamide release by ADP-ribosylating toxins.

The measurement of cholera toxin activity will serve as a model system for other ADPribosylating toxins.

GC/MS nicotinamide detection may be useful in a variety of clinical and laboratory applications, especially when a radioactive assay is not possible. Our goal is to provide a non-radioactive method for the detection and measurement of the activity of ADPribosylating toxins.

Jacobson, E. L., Dame, A. J., Pyrek, J. S., & Jacobson, M. K. (1995). Evaluating the role of niacin in human carcinogenesis. Biochimie, 77, 394-398.

Moss, J., Manganiello, V. C., & Vaughan, M. (1976). Hydrolysis of nicotinamide adenine dinucleotide by choleragen and its A protomer: Possible role in the activation of adenylate cyclase. Proceedings of the National Academy of Science, USA, 73, 4424-4427.

Special thanks to the Concordia University Summer Undergraduate Research Program for funding, Dr. Joel Moss at the National Institute of Health for his advice, and my colleagues Bethany Taylor and Joanna Fridlund for their help and support.



UNIVERSITY

#### **Future Research**

#### References

#### Thanks